Please login to the form below

OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy

Written by Gavin Jones, OPEN Health

The FDA has published their industry guidance on the topic of long term follow up (LTFU) post gene therapy. Please see a link to the full guidance below. In summary, they are stipulating that a good proportion of these therapies will require LTFU of up to fifteen years.

This presents significant challenge to manufacturers given that patients will, in that stretch of time, have multiple changes to their care settings and life circumstances. In addition to this, and if these therapies live up to their promise, treated ‘patients’ will potentially become chronically well and keen to disengage from their previous disease state and their healthcare professionals.

This is a significant challenge but achievable! We have already shared our experienced thinking on this topic and a link to our article is provided below. Our recommendations focus on putting the patient at the centre of a solution and wrapping a, digitally enabled, registry solution around thoughtful patient and healthcare professional engagement.

Please read our full thinking below:

Pink divider

Get in touch

If you would like to discuss further please contact our director of rare disease:

29th January 2020


Company Details

OPEN Health

+44 1628 481112

Contact Website

The Weighbridge
Brewery Courtyard
High Street
United Kingdom

Latest content on this profile

Announcing OPEN Health New Communications CEO, Margot Hannah
OPEN Health is pleased to announce the appointment of Margot Hannah as the new Chief Executive Officer of OPEN Health Communications
OPEN Health
OPEN Health Acquires ARK
OPEN Health has today announced the acquisition of London-based agency ARK to further strengthen omnichannel capabilities
OPEN Health
Rare thoughts & outcomes - navigating pathways to better outcomes in rare

OPEN Health
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D) teams to maximize your training investment. Once you’ve identified some potential collaborators, it’s time to take a closer look at what should be in the packages your training provider offers. Here are six vital features you should prioritize to select the training that will help your team fulfil their potential as partners in delivering high-quality and effective healthcare to patients.
OPEN Health
Maximize your training investments with learning and development specialists
Medical affairs teams must train regularly to stay up to date with existing and emerging therapy areas, products, and devices. But finding time to train is tough, so what can you do to ensure your training programs are as cost-effective, time-efficient, and high quality as possible?
OPEN Health
A day in the life of a PR Account Director
We asked Laura Glover to give us an insight into her role as a PR Account Director at OPEN Health
OPEN Health